miR-101 Inhibiting Cell Proliferation, Migration and Invasion in Hepatocellular Carcinoma through Downregulating Girdin

Cao, Ke; Li, Jingjing; Zhao, Yong; Wang, Qi; Zeng, Qinghai; He, Siqi; Yu, Li; Zhou, Jianda; Cao, Peiguo

doi:10.14348/molcells.2016.2161

Cited by 34 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Under-expression of miR-101 has been identified herein as well as in previous studies in liver cancer [66,67] and CCA [68]. Down- regulated miR-101 was associated with hepatitis B virus infection [69].…”

Section: Figuresupporting

confidence: 74%

Integrative Analysis of Transcriptome and MicroRNome Profiles in Cholangiocarcinoma

Severino¹,

Hasimoto²,

Rodrigues³

et al. 2017

J Cancer Sci Ther

View full text Add to dashboard Cite

Aim: To identify deregulated expression of miRNAs and target genes in cholangiocarcinoma (CCA), as well as drug-gene interactions that may be useful for patient treatment. Methods:We analyzed quantitative transcriptome and miRNA deep sequencing expression data from 45 samples, 36 CCA and 9 histologically normal biliary tissues, obtained from the public repository The Cancer Genome Atlas (TCGA). Bioinformatic methods were used to identify and integrate differential expression of miRNA and transcriptome profiles in CCA vs. normal tissues. Deregulated miRNA and corresponding target genes were identified and mapped into miRNA-mRNA networks. Results:Results showed 64 differentially expressed miRNAs (48 over and 16 under-expressed) between CCA and corresponding normal biliary tissues. Additionally, 432 genes (180 over and 252 under-expressed) were identified between CCA and normal samples. We identified individual miRNAs with the largest number of gene targets. Among these, miR-125a was over-expressed and had the highest number of direct interactions with 33 mRNA targets. miRNAs miR-122 and miR-139 were the under-expressed miRNAs with the highest number of interactions (9 targets each). miR-122 was found to modulate the expression of the transcription factor FOXM1, known to be involved in tumorigenesis and the matrix metalloproteinase MMP7, an important mediator of tumor invasion. miR-148 and miR-194 were predicted to modulate NQO1, which is up-regulated in cancer and associated with treatment resistance in cholangiocarcinoma. Conclusion:The novelty of our study is the identification of complex deregulated networks of miRNAs and target genes in CCA. miRNAs with a large number of targets may have a higher functional impact on cell regulation. These findings contribute for a better understanding of CCA biology. Identified miRNAs and target genes are potential candidates for the design of validation strategies towards the characterization of clinically applicable biomarkers; such biomarkers may be useful for the development of molecularly-targeted therapeutics that can benefit patients.

show abstract

Section: Figuresupporting

confidence: 74%

Integrative Analysis of Transcriptome and MicroRNome Profiles in Cholangiocarcinoma

Severino¹,

Hasimoto²,

Rodrigues³

et al. 2017

J Cancer Sci Ther

View full text Add to dashboard Cite

show abstract

“…Instead, the upregulation of miR-101-3p in plasma of HCC patients has not been previously reported. miR-101 is known to be down-regulated in HCCs where it can act as a tumor suppressor miRNA [ 42 , 43 , 49 ].…”

Section: Discussionmentioning

confidence: 99%

Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common liver cancer and second leading cause of cancer related death worldwide. Most HCCs occur in a damaged cirrhotic background and it may be difficult to discriminate between regenerative nodules and early HCCs. No dependable molecular biomarker exists for the early detection of HCC. MicroRNAs (miRNAs) have attracted attention as potential blood-based biomarkers. To identify circulating miRNAs with diagnostic potential in HCC, we performed preliminary RNAseq studies on plasma samples from a small set of HCC patients, cirrhotic patients and healthy controls. Then, out of the identified miRNAs, we investigated miR-101-3p, miR-106b-3p, miR-1246 and miR-411-5p in plasma of independent HCC patients’ cohorts. The use of droplet digital PCR (ddPCR) confirmed the aberrant levels of these miRNAs. The diagnostic performances of each miRNA and their combinations were measured using Receiver Operating Characteristic (ROC) curve analyses: a classifier consisting of miR-101-3p, miR-1246 and miR-106b-3p produced the best diagnostic precision in plasma of HCC vs. cirrhotic patients (AUC = 0.99). A similar performance was found when the levels of miRNAs of HCC patients were compared to healthy controls (AUC = 1.00). We extended the analyses of the same miRNAs to serum samples. In serum of HCC vs. cirrhotic patients, the combination of miR-101-3p and miR-106b-3p exhibited the best diagnostic accuracy with an AUC = 0.96. Thus, circulating miR-101-3p, miR-106b-3p and miR-1246, either individually or in combination, exhibit a considerable potential value as diagnostic biomarkers of HCC.

show abstract

“…Moreover, miR-101 was dramatically underexpressed in hepatocellular carcinoma tissues, and forced miR-101 expression reduced the oncogenic activities of cancer cells. Moreover, VEGF-C [ 23 ] and Girdin [ 24 ] were identified as its downstream target. In esophageal squamous cell carcinoma, miR-101 downregulation was observed both in cancerous tissues and cell lines.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and prognostic implications of serum miR-101 in osteosarcoma

Yao

Liang

et al. 2018

CBM

View full text Add to dashboard Cite

Blood-circulating microRNAs (miRNAs) have been reported to be used as potential biomarkers in various cancers. MiR-101 has been found to act as a tumor suppressor in many tumor types, but little is known for osteosarcoma. The purpose of this study was to investigate miR-101 expression in osteosarcoma patients and assess its correlation with clinical features and prognosis. Serum samples from 152 osteosarcoma patients and 70 healthy controls were detected using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The data showed that miR-101 expression levels were remarkably underexpressed in serum samples from osteosarcoma patients compared to controls, and the post-treatment serum miR-101 expression was significantly higher than that in the pre-treatment expression. Low serum miR-101 expression was positively associated with advanced clinical stage and distant metastasis. Receiver operating characteristic (ROC) curve analysis showed that serum miR-101 could serve as a useful marker for osteosarcoma diagnosis, with a high sensitivity and specificity. Moreover, patients with high miR-101 expression had longer overall survival and recurrence free survival than those with low miR-101 expression. In addition, both univariate and multivariate analyses showed that serum miR-101 downregulation was associated with shorter overall survival and recurrence free survival. Our present results implicated serum miR-101 might be a useful biomarker for the clinical diagnosis and prognosis of osteosarcoma.

show abstract

miR-101 Inhibiting Cell Proliferation, Migration and Invasion in Hepatocellular Carcinoma through Downregulating Girdin

Cited by 34 publications

References 23 publications

Integrative Analysis of Transcriptome and MicroRNome Profiles in Cholangiocarcinoma

Integrative Analysis of Transcriptome and MicroRNome Profiles in Cholangiocarcinoma

Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma

Diagnostic and prognostic implications of serum miR-101 in osteosarcoma

Contact Info

Product

Resources

About